T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity

T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity

The hostile tumor microenvironment (TME) is a major challenge for the treatment of solid tumors with T-cell receptor (TCR)-modified T-cells (TCR-Ts), as it negatively influences T-cell efficacy, fitness, and persistence. These negative influences are caused, among others, by the inhibitory checkpoin...

Full description

Bibliographic Details
Main Authors: Braun, M. (Author), Brechtefeld, D. (Author), Bürdek, M. (Author), Fetzer, I. (Author), Geiger, C. (Author), Krendl, C. (Author), Mutze, K. (Author), Noessner, E. (Author), Sailer, N. (Author), Salvermoser, M. (Author), Schendel, D.J (Author), Sommermeyer, D. (Author), Wilde, S. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
cancer
immunotherapy
PD-1
PRAME
TCR-T cells
TME
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items